Avalo Therapeutics Engages Investors at Key Conferences
Avalo Therapeutics, Inc. (NASDAQ: AVTX), located in Wayne, Pennsylvania, is a forward-thinking biotechnology firm specializing in the development of innovative treatments targeting immune-mediated inflammatory diseases. The company is excited to announce its participation in several upcoming investor conferences, providing an excellent opportunity to connect with stakeholders and share their vision in the biotechnology space.
Upcoming Conferences Participation
Management at Avalo Therapeutics will present at three notable events in the near future, showcasing the company’s ongoing commitment to advancing treatment options for inflammatory diseases:
Cantor Global Healthcare Conference
Avalo's representatives will take part in a fireside chat at the Cantor Global Healthcare Conference happening soon. This event is a key platform where industry leaders and investors come together to discuss the future of healthcare.
H.C.Wainwright 27th Annual Global Investment Conference
Shortly after the Cantor conference, Avalo will also be featured in a presentation during the H.C.Wainwright 27th Annual Global Investment Conference. This important gathering allows biotech companies to attract interest and support from investors who follow the sector closely.
Stifel 2025 Virtual Immunology and Inflammation Forum
The Stifel Virtual Forum will be another significant event for Avalo, where management will engage in a fireside chat. This forum focuses on immunology and inflammation, making it an ideal venue for Avalo to highlight its innovative therapies.
Importance of Webcasts
For those unable to attend these events in person, Avalo Therapeutics will host live webcasts. Recordings of these presentations will also be available for replay, ensuring that all interested parties can stay informed regarding the latest developments and strategic insights. Interested individuals can find webcasts in the "News / Events" section of the Avalo Therapeutics website.
About Avalo Therapeutics
Avalo Therapeutics is dedicated to creating groundbreaking therapies that address unmet medical needs in areas like hidradenitis suppurativa (HS). The firm’s leading asset, AVTX-009, is currently in a Phase 2 clinical trial and symbolizes their commitment to developing effective treatments for inflammatory diseases.
Innovations Behind AVTX-009
AVTX-009 works as a humanized monoclonal antibody (IgG4) that effectively binds to and neutralizes interleukin-1? (IL-1?), a cytokine that contributes significantly to inflammation and autoimmune disorders. By targeting IL-1?, Avalo aims to address the core issues driving inflammation in various diseases.
Contact Information for Inquiries
For any media or investor inquiries, reach out to:
Christopher Sullivan
CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
Contact Number: 410-803-6793
For additional inquiries regarding relations, connect with:
Lauren Glaser
Meru Advisors
lglaser@meruadvisors.com
Frequently Asked Questions
What is the primary focus of Avalo Therapeutics?
Avalo Therapeutics is focused on developing treatments for immune-mediated inflammatory diseases.
What is AVTX-009?
AVTX-009 is a humanized monoclonal antibody designed to neutralize interleukin-1? to reduce inflammation.
When will Avalo participate in investor conferences?
Avalo is participating in several conferences, including the Cantor Global Healthcare Conference and the H.C.Wainwright conference.
Where can I find the webcasts for these conferences?
The webcasts will be available in the "News / Events" section on the Avalo Therapeutics website.
Who should I contact for media inquiries?
For media inquiries, contact Christopher Sullivan at Avalo Therapeutics.
